Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Immunoinformatic Guided Rational Design of a Next Generation Multi Epitope Based Peptide Vaccine against Marburg Virus Disease Combined with Molecular Docking Studies

Version 1 : Received: 6 May 2022 / Approved: 10 May 2022 / Online: 10 May 2022 (14:16:20 CEST)

How to cite: Mustafa, M.; Shantier, S. Immunoinformatic Guided Rational Design of a Next Generation Multi Epitope Based Peptide Vaccine against Marburg Virus Disease Combined with Molecular Docking Studies. Preprints 2022, 2022050143. https://doi.org/10.20944/preprints202205.0143.v1 Mustafa, M.; Shantier, S. Immunoinformatic Guided Rational Design of a Next Generation Multi Epitope Based Peptide Vaccine against Marburg Virus Disease Combined with Molecular Docking Studies. Preprints 2022, 2022050143. https://doi.org/10.20944/preprints202205.0143.v1

Abstract

Marburg virus disease (MVD) is a hemorrhagic fever and cause death up to 88% of people and is the same as Ebola virus, It is transmitted through skin contact or mucous membrane in the eyes, nose or mouth with blood or body fluids like urine, saliva sweat, feces and by object contaminated with body fluids. Despite these facts, yet there is no approved vaccine have been developed for the eradication of Marburg virus infections. Therefore, this study described a multi epitope-based peptide vaccine against Marburg virus viral protein 35, using several immunoinformatics tools combined with molecular docking studies. Utilizing Vaxijen 2.0 server, the V35 protein revealed to be antigenic with a score of 0.4316. Prediction of the T-cell and B-cell epitopes was then conducted. RTFDAFLGV epitope was found to be the most promising one with binding affinity to the highest numbers of MHC I alleles, a positive score in the Class I immunogenicity study and non-allergen. These results were further confirmed by the good interaction of RTFDAFLGV to the groove of HLA-A*02:01 with binding energy of -8.1 kcal/mole. Finally, the vaccine was cloned in silico to ensure its validity and efficiency of expression. To ensure its safety and immunogenic profile, in-vitro and in-vivo bioassays are recommended to confirm these findings.

Keywords

Marburg virus disease (MVD); Vaccine design; Immunoinformatic; Molecular Docking Study.

Subject

Biology and Life Sciences, Biology and Biotechnology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.